Tirzepatide
US$ 26.20
glp-1 drugs and breast cancer Study links to lower diagnosis rates GLP-1 Receptor Agonists in Breast
Description
The company predicts approximately $3.75 billion in GLP-1RA sales in 2025
Malm-Erjeflt M, Bjrnsdottir I, Vanggaard J, et al
doi: 10.1016/j.eclinm.2024.102726 88
Clinical significance of nonalbuminuric renal impairment in type 2 diabetes
Although the majority of medications work this way, GLP-1s dont
Despite these strengths, the current study has several limitations that need to be acknowledged
